Affiance Financial LLC Boosts Stock Holdings in InspireMD, Inc. (NYSE:NSPR)

Affiance Financial LLC raised its holdings in InspireMD, Inc. (NYSE:NSPR) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 189,122 shares of the company’s stock after purchasing an additional 5,376 shares during the quarter. Affiance Financial LLC owned 0.73% of InspireMD worth $497,000 as of its most recent SEC filing.

Separately, Parkman Healthcare Partners LLC purchased a new position in InspireMD in the 3rd quarter valued at $279,000. Institutional investors own 44.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NSPR. StockNews.com began coverage on InspireMD in a research report on Tuesday, January 21st. They issued a “sell” rating on the stock. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target on the stock.

InspireMD Price Performance

Shares of InspireMD stock opened at $2.83 on Friday. InspireMD, Inc. has a 1 year low of $1.81 and a 1 year high of $3.42. The stock has a 50-day moving average price of $2.83 and a 200 day moving average price of $2.73.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the previous year, the company earned ($0.15) earnings per share. On average, equities analysts forecast that InspireMD, Inc. will post -0.79 earnings per share for the current fiscal year.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.